Antonio Palumbo
Impact in
- Hematology top 0.02%
- Multiple Myeloma Research and Treatments
- Oncology top 0.2%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
Papers in
- Hematology 282
- Multiple Myeloma Research and Treatments 275
- Oncology 155
- Cancer Treatment and Pharmacology 85
- Peptidase Inhibition and Analysis 59
- Co-authors
- Kenneth C. AndersonMario BoccadoroJesús F. San MiguelPieter SonneveldMeletios Α. DimopoulosPaul G. RichardsonPhilippe MoreauMichèle Cavo
- Journals
- Blood (74 papers)Journal of Clinical Oncology (39 papers)Haematologica (14 papers)Leukemia (10 papers)British Journal of Haematology (7 papers)
- Partner nations
- ItalyUnited StatesSpain
In The Last Decade
Antonio Palumbo
304 papers receiving 12.2k citations
Hit Papers
Peers
Comparison fields: 5 of 135
- Hematology 9.8k
- Oncology 5.9k
- Genetics 1.5k
- Molecular Biology 8.0k
- Immunology 1.2k
Countries citing papers authored by Antonio Palumbo
This map shows the geographic impact of Antonio Palumbo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Palumbo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Palumbo more than expected).
Fields of papers citing papers by Antonio Palumbo
This network shows the impact of papers produced by Antonio Palumbo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Palumbo. The network helps show where Antonio Palumbo may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Antonio Palumbo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 53 | |
| 2 | 2019 | 22 | |
| 3 | 2018 | 28 | |
| 4 | 2018 | 34 | |
| 5 | 2016 | 2 | |
| 6 | OUTCOMES FOR OLDER PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE STRATUS (MM-010) TRIAL, A SINGLE-ARM, PHASE 3B STUDY | 2015 | 1 |
| 7 | THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA | 2015 | 1 |
| 8 | 2014 | 14 | |
| 9 | Overall survival of patients with relapsed and refractory multiple myeloma: adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone vs. high-dose dexamethasone | 2014 | 1 |
| 10 | A multinational observational study in multiple myeloma (preamble): initial results of treatment patterns | 2014 | 1 |
| 11 | 2014 | 9 | |
| 12 | 2014 | 10 | |
| 13 | 2013 | 66 | |
| 14 | IMWG consensus on risk stratification in multiple myeloma Hit paper breakdown → | 2013 | 413 |
| 15 | Retrospective analysis of the long term safety of lenalidomide (Len)±dexamethasone (Dex) in relapsed/refractory multiple myeloma (RRMM) patients (pts): analysis of pooled data and incidence rates (IR) of second primary malignancy (SPM) | 2011 | 4 |
| 16 | A phase 3 study to determine the efficacy and safety oflenalidomide combined with melphalan and prednisone in patients= 65 years with newly diagnosed multiple myeloma (NDMM) | 2010 | 12 |
| 17 | 2009 | 46 | |
| 18 | Prolonged therapy with bortezomib plus melphalan-prednisone (vmp) results in improved quality and duration of response in the phase iii vista study in previously untreated multiple myeloma (mm) | 2008 | 7 |
| 19 | TWO DOSE-INTENIVE MELPHALAN REGIMENS (100 MG/M2 VERSUS 200 MG/M2) IN MULTIPLE MYELOMA PATIENTS | 2003 | 12 |
| 20 | REAL TIME QUANTITATIVE PCR SHOWS THAT PERIPHERAK BLOOD STEM CELL (PBPC) HARVESTS ARE SIGNIFICANTILY LESS CONTAMINATED THAN BONE MARROW (BM) IN MULTIPLE MYELOMA PATIENTS (MM). | 1996 | 1 |
About Antonio Palumbo
Antonio Palumbo is a scholar working on Hematology, Oncology, Genetics, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 309 papers that have together received 12.5k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (275 papers), Protein Degradation and Inhibitors (131 papers), Cancer Treatment and Pharmacology (85 papers), Peptidase Inhibition and Analysis (59 papers), Chronic Lymphocytic Leukemia Research (26 papers), Ubiquitin and proteasome pathways (23 papers), Histone Deacetylase Inhibitors Research (18 papers) and Monoclonal and Polyclonal Antibodies Research (17 papers). The work is most often cited by research in Hematology (9.8k citations), Oncology (5.9k citations), Genetics (1.5k citations), Molecular Biology (8.0k citations) and Immunology (1.2k citations). Antonio Palumbo has collaborated with scholars based in Italy, United States and Spain. Frequent co-authors include Kenneth C. Anderson, Mario Boccadoro, Jesús F. San Miguel, Pieter Sonneveld, Meletios Α. Dimopoulos, Paul G. Richardson, Philippe Moreau, Michèle Cavo, María‐Victoria Mateos and Francesca Gay. Their work appears in journals such as Blood, Journal of Clinical Oncology, Haematologica, Leukemia and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.